Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

IMDX vs CDNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDNA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

CDNA Overall Winner 6-Pillar Tally: IMDX 1 – 5 CDNA Matrix Metrics: IMDX 3 – 7 CDNA

As of Nov 19, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas CDNA carries 32.0/100 (SELL) at $71.92 (46.0x Forward P/E, 1.6% operating margin).

  • Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. CDNA 32.0/100 SELL), CDNA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (1.6% vs. -1883.2% operating margin) and revenue trajectory (+39.3% vs. +115.0% YoY).
  • Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMDX vs CDNA
IMDX NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap $52.1M
TTM Revenue $2.0M
Forward P/E N/M
Beta / 30D Vol 2.91β · 76% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 50.0 Fund 40.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.7%), weak momentum, RSI 22
RSI-14: 21.9 · SMA20: $2.51 · SMA50: $3.10
CDNA NASDAQ Head-to-Head Winner
CareDx, Inc.
Services-Medical Laboratories
$71.92
-3.39% 1D
Market Cap $3.9B
TTM Revenue $497M
Forward P/E 46.0x
Beta / 30D Vol 1.22β · 97% Vol
Unified Composite Score
32.0 / 100 SELL
Tech 31.0 Fund 48.0 Flow 70.0 Mom 36.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.4 · SMA20: $77.68 · SMA50: $68.21

6-Pillar Scorecard Institutional Category Breakdown (IMDX 1 – 5 CDNA)

Columns: Metric · IMDX · CDNA
1. Valuation Multiples CDNA
Forward P/E N/M 46.0x
Trailing P/E N/M 31.5x
PEG Ratio N/M N/M
EV / Revenue 18.8x 7.4x
2. Growth & Scale IMDX
Revenue Growth (YoY) +115.0% +39.3%
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $2.0M $497M
Market Cap $52.1M $3.9B
3. Profitability & Quality CDNA
Gross Margin 55.6% 71.0%
Operating Margin -1883.2% 1.6%
Net Profit Margin 0.0% 25.9%
Return on Equity (ROE) -23603.1% 33.0%
4. Balance Sheet & Cash Flow CDNA
Cash Generation (TTM) -$31M $60M
Cash Flow Margin N/A 12.0%
Net Cash / Leverage $15M Net Cash $221M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CDNA
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 99.4% (12th %ile) 64.6% (20th %ile)
Put/Call OI Skew 0.08x (Call-Skewed) 0.27x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CDNA
OpEx & R&D Intensity N/A 69.4% of Rev ($345M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMDX (3) vs CDNA (7)
Institutional Metric IMDX CDNA Criterion Row Edge
Market Capitalization
Scale
$52.1M $3.9B Larger Scale CDNA
Trailing P/E Ratio
Valuation
N/M 31.5x Lower Multiple CDNA
Forward P/E Ratio
Valuation
N/M 46.0x Lower Multiple CDNA
Revenue Growth (YoY)
Growth
+115.0% +39.3% Higher Growth IMDX
Operating Margin (TTM)
Profitability
-1883.2% 1.6% Higher Margin CDNA
Net Profit Margin
Profitability
0.0% 25.9% Higher Margin CDNA
Return on Equity (ROE)
Capital Efficiency
-23603.1% 33.0% Higher ROE CDNA
52-Week Range Position
Momentum
3% ($2–$8) 75% ($15–$91) Stronger Trend CDNA
Beta / 30D Volatility
Risk Regime
2.91β · 76% Vol 1.22β · 97% Vol Lower Realized Risk IMDX
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 32.0 / 100 (SELL) Higher Composite IMDX
Trailing 12M Revenue (USD)
Operating Scale
$2.0M $497M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
55.6% 71.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.8x EV/Rev N/M PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($15M Net Cash) $60M ($221M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDNA +46.7 pp
IMDX: -45.03% · CDNA: +1.67%
3M Horizon CDNA +109.7 pp
IMDX: -61.75% · CDNA: +47.95%
6M Horizon CDNA +305.2 pp
IMDX: -71.77% · CDNA: +233.43%
1Y Horizon CDNA +430.13 pp
IMDX: -73.78% · CDNA: +356.35%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IMDX Revenue CDNA Revenue IMDX Op. Margin CDNA Op. Margin Margin Leader
FY2018 N/A $80M N/A -20.3% CDNA
FY2019 N/A $130M N/A -19.3% CDNA
FY2020 $0M $190M -2443.3% -11.7% CDNA
FY2021 $0M $300M -2444.3% -10.0% CDNA
FY2022 $0M $320M -1878.6% -24.0% CDNA
FY2023 $0M $280M -1672.4% -72.5% CDNA
FY2024 $0M $330M -3245.1% 12.2% CDNA
FY2025 $0M $380M -1260.8% -8.1% CDNA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMDX BREAKDOWN
117d in phase · OBV DISTRIBUTION
Current IV 99.4%
IV Percentile 12th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IMDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDNA CONSOLIDATION
33d in phase · OBV NEUTRAL
Current IV 64.6%
IV Percentile 20th %ile
Put/Call OI Skew 0.27x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMDX Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $52.1M market capitalization and -1883.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDNA Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $3.9B market capitalization and 1.6% operating margin.
OpEx & R&D Reinvestment 69.4% of Rev ($345M)
90D Engineering Disclosures 0 Published

Investor FAQ IMDX vs CDNA Key Questions & Quantitative Answers

As of Nov 19, 2026, CareDx, Inc. (CDNA) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas CDNA carries 32.0/100 (SELL) at $71.92 (46.0x Forward P/E, 1.6% operating margin). Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. CDNA 32.0/100 SELL), CDNA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (1.6% vs. -1883.2% operating margin) and revenue trajectory (+39.3% vs. +115.0% YoY). Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile CDNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMDX leads the Growth & Scale pillar: IMDX posts +115.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (55.6% gross margin, -1883.2% operating margin), compared with CDNA at +39.3% YoY revenue growth and N/A YoY earnings growth on $497M TTM revenue (71.0% gross margin, 1.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IMDX cumulative revenue shifted N/A while CDNA shifted +375.0%. In operating R&D and SG&A reinvestment, IMDX deploys N/A (0 90-day corporate R&D disclosures) versus 69.4% of Rev ($345M) (0 disclosures) for CDNA.

CDNA screens cheaper on headline valuation multiples. IMDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.8x EV/Revenue (unreported FCF margin), whereas CDNA trades at 46.0x Forward P/E, 31.5x Trailing P/E, N/M PEG, and 7.4x EV/Revenue (12.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMDX (-23603.1% ROE) versus CDNA (33.0% ROE) capital efficiency.

In options market volatility and institutional positioning, IMDX carries 99.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 76% Vol realized risk). By comparison, CDNA carries 64.6% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.27x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.22β · 97% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.